TAIWAN MAKING STRIDES IN MANUFACTURING MONOCLONAL ANTIBODIES
January 7th, 2015
A major pharma manufacturer in Taiwan has claimed his US-based company’s success in making monoclonal antibodies on the island will be continued, creating a segment that should be able fend off competition from companies in other emerging market countries, notably India. With JHL Biotech, (founded in California in 2012), and locally-initiated EirGenix Inc, Taiwan currently has two operators of plants commercially manufacturing antibodies used mainly in early-stage clinical trials.“[Since our Taiwan plant’s launch in early 2014], we have booked more than ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.